GLUE: רווח נקי למניה ב-12 החודשים האחרונים monterosatx.com
Monte Rosa Therapeutics (GLUE) is developing an asset-light model by outsourcing drug production to third-party contractors. The 12-month rolling EPS on the precise GURU.Markets chart demonstrates profit dynamics, where -1.54 serves as the final level marker. The absence of revenue leaves the company dependent on investments, while the success of protein degradation innovations supported by Roche determines the viability of the base.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_GLUE_-_Monte-Rosa-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Monte Rosa Tx - רווח נקי למניה (EPS TTM) GLUE (תקופה 04.07.2022 - 10.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Monte Rosa Therapeutics
The stability of Monte Rosa Therapeutics (GLUE) relies on partnerships with pharmaceutical behemoths, yet the actual business value depends on the success of clinical trials for molecular glues. The trailing 12-month net income per share trend reflects the final profit distributed across the total share issuance, allowing investors to separate speculative noise from the company's actual ability to generate capital over the long term.
